



King's Research Portal

DOI:

[10.1016/j.jad.2023.01.114](https://doi.org/10.1016/j.jad.2023.01.114)

Document Version

Publisher's PDF, also known as Version of record

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Pearson, O., Uglik-Marucha, E., Miskowiak, K., Cairney, S., Rosenzweig, I., Young, A., & Stokes, P. (2023). The relationship between sleep disturbance and cognitive impairment in mood disorders: A systematic review. *Journal of Affective Disorders*, 327, 207–216. <https://doi.org/10.1016/j.jad.2023.01.114>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Review Article

The relationship between sleep disturbance and cognitive impairment in mood disorders: A systematic review

Oliver Pearson^{a,b,*}, Nora Uglík-Marucha^a, Kamilla W. Miskowiak^c, Scott A. Cairney^{d,e},
Ivana Rosenzweig^{f,g}, Allan H. Young^{b,h}, Paul R.A. Stokes^{b,h}

^a Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, SE5 8AF London, United Kingdom

^b Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry & Psychology and Neuroscience, King's College London, United Kingdom

^c Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

^d Department of Psychology, University of York, York YO10 5DD, United Kingdom

^e York Biomedical Research Institute, University of York, York YO10 5DD, United Kingdom

^f Sleep and Brain Plasticity Centre, Department of Neuroimaging, IoPPN, KCL, United Kingdom

^g Sleep Disorders Centre, Guy's and St Thomas' Hospital, G8TT NHS, London, United Kingdom

^h South London and Maudsley NHS Foundation Trust, Bethlem Royal Hospital, Monks Orchard Road, Beckenham, Kent BR3 3BX, United Kingdom



ARTICLE INFO

Keywords:

Sleep disturbance

Sleep disorder

Insomnia

Hypersomnia

Cognitive impairment

Bipolar disorder

Major depressive disorder

ABSTRACT

Background: Cognitive impairment experienced by people with bipolar disorders (BD) or major depressive disorder (MDD) is associated with impaired psychosocial function and poorer quality of life. Sleep disturbance is another core symptom of mood disorders which may be associated with, and perhaps worsen, cognitive impairments. The aim of this systematic review was to critically assess the relationship between sleep disturbance and cognitive impairment in mood disorders.

Methods: In this systematic review, relevant studies were identified using electronic database searches of PsycINFO, MEDLINE, Embase and Web of Science.

Findings: Fourteen studies were included; eight investigated people with BD, five investigated people with MDD, and one included both people with MDD and people with BD. One study was an intervention for sleep disturbance and the remaining thirteen studies used either a longitudinal or cross-sectional observational design. Ten studies reported a significant association between subjectively measured sleep disturbance and cognitive impairment in people with MDD or BD after adjusting for demographic and clinical covariates, whereas no such association was found in healthy participants. Two studies reported a significant association between objectively measured (actigraphy or polysomnography) sleep abnormalities and cognitive impairment in mood disorders. One study of cognitive behavioural therapy for insomnia modified for BD (CBTI-BD) found an association between improvements in sleep and cognitive performance in BD.

Interpretation: There is preliminary evidence to suggest a significant association between sleep disturbance and cognitive impairment in mood disorders. These findings highlight the need for further research of sleep disturbances and cognitive impairment in people with mood disorders.

1. Introduction

Cognitive impairment in people with bipolar disorders (BD) or major depressive disorder (MDD) is associated with poorer psychosocial functioning (McIntyre et al., 2013; O'Donnell et al., 2017), poor illness prognosis (Martino et al., 2017; Zhang et al., 2020), and poor quality of life (Cambridge et al., 2018; Depp et al., 2012). Meta-analyses have

reported significant deficits in executive function, memory and attention in people with MDD currently experiencing a depressive episode, with effect sizes ranging from $d = -0.32$ to -0.97 (Rock et al., 2014; Snyder, 2013). In BD, a meta-analysis has reported moderate effect size deficits in executive function in people experiencing depressive episodes ($d = -0.55$) and large effect sizes in people experiencing manic episodes ($d = -0.72$) (Kurtz and Gerraty, 2009). However, cognitive impairment is not

* Corresponding author at: Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology & Neuroscience, King's College London, 16 De Crespigny Park, London SE5 8AF, United Kingdom.

E-mail address: oliver.pearson@kcl.ac.uk (O. Pearson).

<https://doi.org/10.1016/j.jad.2023.01.114>

Received 27 July 2022; Received in revised form 22 January 2023; Accepted 30 January 2023

Available online 3 February 2023

0165-0327/© 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

confined to mood episodes, but persists during euthymia in MDD and BD. For example, [Rock et al. \(2014\)](#) found moderate effect size deficits in executive function and attention in people with remitted MDD, while [Semkovska et al. \(2019\)](#) identified deficits in working memory and long-term memory. In BD, medium to large effect size deficits in executive function, verbal memory, sustained attention and psychomotor speed have been identified by a meta-analysis ([Bora et al., 2009](#)). There is considerable heterogeneity in cognitive impairments across people with mood disorders and approximately 35 % of people with MDD ([Pu et al., 2018](#)) and 20–40 % of people with BD ([Burdick et al., 2014](#); [Jensen et al., 2016](#)) experience moderate to severe impairment in several cognitive domains.

The aetiology of cognitive impairment in mood disorders is not fully understood ([Depp et al., 2016](#)), and determining how cognitive impairment is mediated in MDD and BD is a key priority. Sleep disturbance may be one contributing factor. Sleep disturbances are core features of manic episodes, hypomanic episodes and major depressive episodes manifesting as insomnia or hypersomnia and fatigue in major depressive episodes and a decreased need for sleep in manic or hypomanic episodes ([American Psychiatric Association, 2013](#)). There is also growing evidence to suggest that sleep disturbance persists during euthymia in a substantial proportion of people with mood disorders. Clinically significant sleep disturbances are reported by 70 % of euthymic people with BD ([Harvey et al., 2005](#)) and 44–60 % of euthymic people with MDD ([Carney et al., 2007](#); [Iovieno et al., 2011](#); [Nierenberg et al., 1999](#)). Moreover, sleep disturbance is associated with higher rates of relapse and suicide attempts in both BD ([Sylvia et al., 2012](#)) and MDD ([Li et al., 2012](#)). Sleep disturbances escalate just before manic and depressive relapse in BD, and worsen during these episodes ([Jackson et al., 2003](#)).

There is strong evidence detailing the negative effects of sleep disturbance on many aspects of cognition in healthy individuals ([Krause et al., 2017](#)), including fragmented memory loss ([Ashton et al., 2020](#)) and impaired suppression of unwanted thoughts ([Harrington et al., 2021](#); [Harrington and Cairney, 2021](#)). Recently, evidence has emerged to suggest an association between sleep disturbance and cognitive impairment in mood disorders. For example, [Bradley et al. \(2020\)](#) found that people with BD and abnormal sleep patterns, as measured by sleep actigraphy, performed significantly poorer than healthy participants in cognitive performance, whereas people with BD and normal sleep patterns did not significantly differ from healthy participants. As yet, there has not been a systematic review of the relationship between sleep disturbance and cognitive impairment in mood disorders.

The aim of this systematic review was to critically analyse the relationship between sleep disturbance and cognitive impairment in MDD and BD, and to examine relevant factors affecting this relationship.

2. Methods

2.1. Literature search

Two reviewers (OP and NUM) independently performed the literature search in February 2021. Relevant studies were identified using electronic database searches of PsychINFO, MEDLINE, Embase and Web of Science. The following search string was used: [(sleep disturb*) OR (sleep disorder*) OR (insomn*) OR (hypersomn*)] AND [(cognitive impair*)] AND [(bipolar*) OR (depress*)]. Papers were extracted from inception until February 2021. Only studies written in English were considered. Both reviewers independently reviewed the title and abstract of each paper to assess relevance, and then reviewed the full text of relevant articles to assess whether they met the inclusion and exclusion criteria. There were seven disagreements between the reviewers, which were all resolved by consensus. This systematic review followed PRISMA 2020 guidelines ([Page et al., 2021](#)), although a study protocol was not registered.

2.2. Inclusion and exclusion criteria

All databases were screened following the same protocol. Included studies were required to include participants with a lifetime diagnosis of MDD, BD-I or BD-II, meeting criteria for ICD-9 ([World Health Organization, 1988](#)) or subsequent editions, or DSM-III ([American Psychiatric Association, 1980](#)) or subsequent editions. Included studies were required to measure both sleep disturbance and cognition. Studies were excluded if they: did not primarily include people with a diagnosis of MDD, BD-I or BD-II; included only participants with dysthymia or cyclothymia or with comorbid neurological disorders (e.g. dementia, epilepsy or stroke) or mild cognitive impairment (MCI); included primarily older participants; were follow-up studies or case reports; were not published by a peer-reviewed scientific journal.

2.3. Data extraction

The following data were extracted: study name and year; participant sample size, age range, disorder and mood state of participants, measures of sleep and cognition, a summary of main findings, in particular the association between measures of sleep and cognition, and study limitations.

2.4. Quality assessment

Two reviewers (OP and NUM) independently assessed the quality of included studies using the Quality Assessment Tool for Quantitative Studies, developed by the Effective Public Health Practice Project (EPHPP) ([Thomas et al., 2003](#)). The following criteria of each study were rated as either strong, moderate or weak: selection bias, design, confounders, blinding, data collection methods, and withdrawals/drop-outs (if applicable). These ratings were aggregated to form a global rating: studies were rated globally as strong if they received no weak ratings; moderate if they received one weak rating; and weak if they received two or more weak ratings. There were eight disagreements between the reviewers, which were all resolved by consensus.

3. Results

A total of 3094 studies were identified, which was reduced to 2208 after duplicates were removed. Following primary assessment of titles and abstracts, this was reduced to 30 studies. Based on secondary assessment of full texts, we included 14 studies that fulfilled the eligibility criteria (please see [Fig. 1](#) for further details).

3.1. Studies

Of the 14 included studies, eight included people with BD ([Boland et al., 2015](#); [Bradley et al., 2020](#); [Kanady et al., 2017](#); [Laskemoen et al., 2019](#); [Samalin et al., 2017](#); [Ullah, 2017](#); [Volkert et al., 2015](#)), five included people with MDD ([Cabanel et al., 2019](#); [Cha et al., 2019](#); [Müller et al., 2017](#); [Peng et al., 2018](#); [Wilckens et al., 2020](#)), and one included both people with MDD and people with BD ([Soehner and Harvey, 2012](#)) (see [Table 1](#)). These studies were published between years 2012–2020. A total of 2353 people with mood disorders were included in these studies, 1083 people with MDD and 1270 people with BD. The mood state of participants varied across studies. Of the eight BD studies, six included only euthymic participants ([Boland et al., 2015](#); [Kanady et al., 2017](#); [Russo et al., 2015](#); [Samalin et al., 2017](#); [Volkert et al., 2015](#)), whereas two included participants in any mood state ([Bradley et al., 2020](#); [Laskemoen et al., 2019](#)). Of the five MDD studies, four only included people currently experiencing a major depressive episode (MDE); however, [Wilckens et al.](#) included only people with remitted depression. The one study of people with MDD or BD included participants in any mood state ([Soehner and Harvey, 2012](#)).




Fig. 1. PRISMA 2020 Flow Diagram of study selection process.

3.2. BD results

Six of the eight BD studies reported associations between sleep disturbance and cognitive impairment.

3.2.1. Studies including participants in a euthymic mood state

Kanady et al. (2017) found that greater sleep time variability, as measured by ISI (please see Table 1 for details of measures), predicted poorer working memory ($p < 0.01$) and verbal learning performance ($p < 0.01$) in euthymic BD participants. Furthermore, following treatment with cognitive behaviour therapy for insomnia modified for bipolar disorder (CBTI-BD), a reduction in total wake time predicted improved working memory ($p < 0.05$) and a reduction in sleep time variability predicted improved verbal learning ($p < 0.05$) (Kanady et al., 2017). Samalin et al. (2017) found that sleep disturbances as measured by PSQI were indirectly associated with cognitive function potentially mediated via residual depressive symptoms and perceived cognitive performance, in euthymic BD participants ($p = 0.001$). Another study by Samalin et al. (2016) reported that euthymic BD participants with impaired cognitive functioning had significantly higher PSQI scores ($p < 0.02$), and thus more severe sleep disruptions, than participants with satisfactory cognitive functioning. Volkert et al. (2015) reported that euthymic BD participants experiencing persistent sleep disturbances as measured by MADRS show more severe cognitive dysfunctions ($p < 0.05$). Russo et al.

(2015) found that sleep disturbance as measured by ESS and PSQI was significantly negatively associated with social cognition ($r = -0.273$, $p = 0.004$), but only associated at a trend level with working memory ($r = -0.179$, $p = 0.061$) and visual learning ($r = -0.161$, $p = 0.094$), in euthymic BD participants. Boland et al. (2015) reported no significant associations between sleep disturbance (including objective parameters: wake after sleep onset, total sleep duration, and sleep efficiency) and cognition, except for a significant negative correlation between daytime dysfunction due to sleep disturbance and working memory ($r = -0.57$, $p = 0.03$), in euthymic BD participants.

3.2.2. Studies including participants in any mood state

Laskemoen et al. (2019) found significant associations between insomnia as measured by IDS-C and processing speed ($p < 0.001$), insomnia and inhibition ($p < 0.01$), hypersomnia and processing speed ($p < 0.01$), and hypersomnia and inhibition ($p < 0.05$) in people with BD, in any mood state, whereas no association between sleep disturbances and cognition was found in healthy participants. Bradley et al. (2020) found that people with BD, in any mood state, with normal sleep patterns were not significantly different to healthy participants in cognitive functions, but people with BD and sleep disturbance (including objective measures) performed significantly worse in cognitive tests than healthy participants ($p < 0.001$).

Table 1
Characteristics and findings of studies examining sleep disturbance and cognitive impairment in MDD.

Study	Mood disorder (s) studied	Participants	Measures	Main findings	Limitations
Cabanel et al., 2019	MDD	Total N = 63 N = 34 participants with MDD, currently experiencing an MDE (27 with single and 7 with recurrent depression; 9 with comorbid anxiety disorders), mean age 33.0 ± 8.9 N = 29 healthy participants, mean age 31.5 ± 7.8	Sleep: PSQI Cognition: TMT-A, TMT-B	People with MDD and severely impaired sleep quality (PSQI > 10) had significantly poorer performance on the TMT-A (visuomotor processing speed; $p = 0.011$) and the TMT-B (executive function; $p = 0.015$), than people with MDD and normal or only moderately impaired sleep quality (PSQI > 10).	The use of subjective measure of sleep instead of objective sleep battery. Neuropsychological assessment only evaluated a subdomain of executive functions. Particularly small sample size.
Cha et al., 2019	MDD	Total N = 200, aged 18 to 65 N = 100 participants with recurrent MDD, currently experiencing an MDE N = 100 sex-, age-, education-matched healthy participants	Sleep: PSQI Cognition: computerised cognitive assessment tool THINC-integrated tool that included CRT, the One Back Memory task, DSST, TMT-B, PDQ-5-D.	Sleep quality predicted impairments in subjective cognitive performance ($p < 0.001$) and objective cognitive impairments ($p = 0.017$). Depression severity was a partial mediator of the relationship between subjective cognitive function and sleep quality ($B = -0.43$; 95 % CI, $-0.56, -0.33$). After controlling for the depression severity, the direct effect of sleep quality on subjective cognition performance remained significant ($B = -0.18$; 95 % CI, $-0.30, -0.07$).	The use of subjective measure of sleep instead of objective sleep battery. Complete case analysis of cognitive tests resulting in low statistical power.
Wilckens et al., 2020	MDD	Total N = 53 euthymic participants, aged 48 to 79 years of age N = 17 participants with recurrent MDD N = 36 participants with no recurrent MDD N = 28 participants with no lifetime MDD N = 25 participants with lifetime MDD	Sleep: two nights of PSG Cognition: computer-based task-switching paradigm	Higher wake after sleep onset and shorter total sleep time were linearly associated with slower response time across single-task ($p = 0.10$) and switching blocks ($p = 0.005$); however, these associations were not specific to MDD.	Participants with history of MDD were more likely to take antidepressants at the time of the study, thus possibly affecting sleep and/or cognition. Did not exclude ages >65. Particularly small sample size.
Müller et al., 2017	MDD	Total N = 154, aged 19–89 N = 154 MDD participants currently experiencing an MDE	Sleep: SQH Cognition: SQH (items pertaining to daytime attention deficits and memory complaints only)	25–40 % of participants with MDD reported ‘almost always’ daytime sleepiness, non-restorative sleep, attention deficits or memory complaints, with significant correlations between these variables ($p < 0.05$), as well as curvilinear associations between sleep duration and sleep quality (quadratic contrast, $p < 0.05$).	The use of subjective measure of sleep instead of objective sleep battery. Did not use a validated measure of cognition. No control group.
Peng et al., 2018	MDD	Total N = 178, aged 15–30 N = 128 first-episode MDD participants experiencing an MDE N = 50 healthy participants	Sleep: PSQI Cognition: MCCB	No significant association between cognition and sleep disturbance ($r = 0.029, p = 0.219$) in adolescents with first episode MDD.	The use of subjective measure of sleep instead of objective sleep battery. Included participants aged <18.
Boland et al., 2015	BD	Total N = 48, aged 18–65 N = 24 euthymic BD participants N = 24 healthy participants	Sleep: ISI, UCII, PSQI, wrist actigraphy Cognition: KBIT-II, DKEFS (Stroop subtest only), Tower of London, CVLT-II, WMS-III (digit span subtest only)	No significant associations between sleep disturbance (including objective measures) and cognition, except for a significant negative correlation between daytime dysfunction due to sleep disturbance and working memory ($r = -0.57, p = 0.03$).	Particularly small sample size.
Bradley et al., 2020	BD	Total N = 88, aged 18–65 N = 46 BD participants, in any mood state N = 42 healthy control participants	Sleep: wrist actigraphy Cognitive assessment: NART, PVT, ANT, DSST, NSMT	People with BD with normal sleep patterns were not significantly different to healthy participants in cognitive functions, but people with BD and sleep disturbance (including objective measures) performed significantly worse in cognitive tests than healthy participants ($p < 0.001$).	Did not adjust for the mood state of participants. Particularly small sample size.
Kanady et al., 2017	BD	Total N = 66, aged 18–65 47 euthymic BD participants with	Sleep: ISI, PSQI, DSISD, sleep diary	Greater sleep time variability predicted poorer working memory	

(continued on next page)

Table 1 (continued)

Study	Mood disorder (s) studied	Participants	Measures	Main findings	Limitations
		comorbid insomnia 19 euthymic BD participants without sleep disturbance in the last six months	Cognition: N-Back Task and WMS-III (digit span subtest only)	($p < 0.01$) and verbal learning performance ($p < 0.01$) in BD. Furthermore, following treatment of cognitive behaviour therapy for insomnia modified for bipolar disorder (CBTI-BD), a reduction in total wake time predicted improved working memory ($p < 0.05$) and a reduction in sleep time variability predicted improved verbal learning ($p < 0.05$).	No healthy control group. Particularly small sample size.
Laskemoen et al., 2019	BD	Total $N = 979$, aged 18–65 $N = 340$ BD participants, in any mood state $N = 457$ schizophrenia participants $N = 182$ healthy control participants	Sleep: IDS-C (items pertaining to sleep disturbance) Cognition: MCCB	Significant associations between insomnia and processing speed ($p < 0.001$), insomnia and inhibition ($p < 0.01$), hypersomnia and processing speed ($p < 0.01$), and hypersomnia and inhibition ($p < 0.05$) in people with BD, whereas no association between sleep disturbances and cognition was found in healthy participants.	The use of subjective measure of sleep instead of objective sleep battery. Did not adjust for the mood state of participants.
Russo et al., 2015	BD	Total $N = 117$, aged 18–65 $N = 117$ euthymic BD participants	Sleep: ESS, PSQI Cognition: MCCB	Sleep disturbance was significantly negatively associated with social cognition ($r = -0.273$, $p = 0.004$), and approached significance with working memory ($r = -0.179$, $p = 0.061$) and visual learning ($r = -0.161$, $p = 0.094$). Path analyses indicated that social cognition and working memory were directly (negatively) predicted by sleep disruptions.	No control group. Only used subjective measures of sleep.
Samalin et al., 2017	BD	Total $N = 468$, aged >18 $N = 468$ euthymic BD participants	Sleep: PSQI Cognition: VAS and FAST	Sleep disturbances were indirectly associated with functioning (including cognition) via residual depressive symptoms and perceived cognitive performance ($p = 0.001$).	The use of subjective measures of cognitive functioning and sleep instead of objective neuropsychological and sleep batteries. Did not exclude ages >65 . No control group.
Samalin et al., 2016	BD	Total $N = 468$, mean age 47.7 ± 12.5 $N = 468$ adult outpatients with bipolar I disorder or bipolar II disorder in an euthymic period	Sleep: PSQI Cognition: VAS and FAST	Participants with impaired cognitive functioning had significantly higher scores ($p < 0.02$), and thus more severe sleep disruptions, on PSQI than participants with satisfactory cognitive functioning.	The use of subjective measures of cognitive functioning and sleep instead of objective neuropsychological and sleep batteries. Did not exclude ages >65 . No control group.
Volkert et al., 2015	BD	Total $N = 140$, aged 18–65 $N = 70$ euthymic BD participants $N = 70$ healthy participants	Sleep: MADRS (item pertaining to sleep disturbance) Cognition: TAP, CVLT, TOL, RWT	People with BD suffering from persistent sleep disturbances show more severe cognitive dysfunctions ($p < 0.05$).	Did not use a validated measure of sleep disturbance.
Soehner and Harvey, 2012	BD & MDD	Total $N = 5692$, aged >18 , in any mood state $N = 3711$ participants with no mood or anxiety disorder $N = 327$ participants with mood disorders only $N = 1137$ participants with anxiety disorders only $N = 517$ participants with comorbid mood and anxiety disorders	Sleep: series of self-report questions Cognition: items from WHO-DAS pertaining to cognition	Participants with a mood disorder and any insomnia symptom in the past year had significantly greater 30-day cognitive impairment than participants with a mood disorder and no insomnia symptoms in the past year ($p = 0.004$).	Subjective measures of sleep and cognition.

Abbreviations: TMT, Trail Making Test part A and B; CRT: Choice Reaction Time; DSST, Digit Symbol Substitution Test; PDQ-5-D, Perceived Deficits Questionnaire 5-item for Depression; PSG, polysomnography; MCI, mild cognitive impairment; SQH, Sleep Quality in Hospital settings in German language (Fietze et al., 2008); PSQI, Pittsburgh Sleep Quality Index (Buysse et al., 1989); WTAR, Wechsler Test of Adult Reading (Wechsler, 2001); WMS-III, Wechsler Memory Scale-III (Wechsler, 1997); MCCB, MATRICS Consensus Cognitive Battery (Wysokinski et al., 2014); ISI, Insomnia Severity Index (Morin, 1993); DSISD, Duke Structured Interview for Sleep Disorder (American Psychiatric Association and American Psychiatric Association, 2013); IDS-C, Inventory of Depressive Symptoms — Clinician rated scale (Rush et al., 1996); SADS-C, Schedule for Affective Disorders and Schizophrenia-Change (Endicott and Spitzer, 1987); MADRS, Montgomery–Asberg Depression Rating Scale (Montgomery and Åsberg, 1979); UCII, Unstructured Clinical Interview for Insomnia; KBIT-II, Kaufman Brief Intelligence Test Second Edition (Kaufman, 1990); DKEFS, Delis-Kaplan Executive Functioning System (Delis et al., 2004); TOL, Tower of London (Shallice, 1982); CVLT, California Verbal Learning Test (Niemann et al., 2011); CVLT-II, California Verbal Learning Test Second Edition (Woods et al., 2006); NART, National Adult Reading Test (Nelson, 1982); PVT, Psychomotor vigilance Test (Dinges and Powell, 1985); ANT, Attention Network Test (Fan et al., 2002); DSST, Digit Symbol Substitution Test (Wechsler, 1997); NSMT, Newcastle Spatial

Memory Task (Pariante et al., 2012); VAS, visual analogic scale (Samalin et al., 2014); FAST, Functioning Assessment Short Test (Rosa et al., 2007); STAN, South Texas Assessment of Neurocognition (Glahn et al., 2010); TAP, Test battery of Attentional Performance (Zimmermann and Fimm, 2002); RWT, Regensburger Wortflüssigkeits Test (Aschenbrenner et al., 2000); ESS, Epworth Sleepiness Scale (Johns, 1991); WHO-DAS, World Health Organization Disability Assessment Schedule-II.

3.3. MDD results

3.3.1. Studies including participants in a euthymic mood state

In a study of euthymic people with remitted MDD, Wilckens et al. (2020) reported that higher wake after sleep onset (i.e., longer periods of wakefulness occurring after defined sleep onset), and shorter total sleep time, as measured by PSG, were linearly associated with slower response time across single-task ($p = 0.10$) and switching blocks ($p = 0.005$) considered a proxy for condition-independent psychomotor slowing (White et al., 1997); however, these associations were also observed in healthy controls and therefore not specific to MDD.

3.3.2. Studies including participants in a depressive mood state

Müller et al. (2017) found that 25–40 % of MDD participants experiencing an MDE reported ‘almost always’ for daytime sleepiness, non-restorative sleep, attention deficits or memory complaints, as measured by SQH, with significant correlations between these variables ($p < 0.05$), as well as curvilinear associations between sleep duration and sleep quality (quadratic contrast, $p < 0.05$). Cabanel et al. (2019) reported that MDD participants experiencing an MDE with severely impaired sleep quality (PSQI > 10) had significantly poorer performance on the TMT-A (visuomotor processing speed; $p = 0.011$) and the TMT-B (executive function; $p = 0.015$) than those experiencing an MDE but with normal or moderately impaired sleep quality (PSQI < 10). In a study of MDD participants experiencing an MDE, Cha et al. (2019) found that sleep quality as measured by PSQI predicted impairments in subjective cognitive performance ($p < 0.001$) and objective cognitive impairments ($p = 0.017$). Depression severity was a partial mediator of the relationship between subjective cognitive function and sleep quality ($B = -0.43$; 95 % CI, $-0.56, -0.33$; $B = -0.18$; 95 % CI, $-0.30, -0.07$ after controlling for depression severity). However, Peng et al. (2018) reported no significant association between cognition and sleep disturbance as measured by PSQI ($r = 0.029$, $p = 0.219$) in adolescents with first episode MDD, experiencing an MDE.

3.4. Results in mixed MDD & BD groups

Soehner and Harvey (2012) ($N = 639$ MDD participants; $N = 138$ BD participants, in any mood state) reported that participants with a mood disorder and insomnia in the past year experienced significantly greater cognitive impairment in the past 30 days than participants with a mood disorder and no insomnia symptoms in the past year ($p = 0.004$).

3.5. Methodological quality assessment

Methodological quality assessment of studies using the EPHPP Quality Assessment Tool for Quantitative Studies (Thomas et al., 2003) are displayed in Supplementary Table 1. Selection bias was generally rated as moderate because in most studies participants were sampled from either outpatient clinics or inpatient settings. Study design was generally rated as weak because most were cross-sectional. Most studies controlled for at least 80 % of relevant confounding variables, such as age, coffee consumption etc. Blinding was rated as moderate if it was not described, as was the case in almost all studies. Most studies used validated and reliable measures for sleep disturbance (e.g. Pittsburgh Sleep Quality Index, PSQI; Buysse et al., 1989) and cognition (e.g. MATRICS Consensus Cognitive Battery, MCCB; Wysokinski et al., 2014), and were therefore rated strong. Where applicable, withdrawals were reported satisfactorily by most studies. There was no association between global rating and positivity of findings.

4. Discussion

Fourteen studies were included in this review, for which quality assessment ranged from weak to strong. Ten of the twelve studies that measured sleep disturbance using subjective measures in participants with either MDD or BD found a significant association between sleep disturbance and cognitive impairment when adjusting for demographic and clinical covariates. In contrast, no significant association was reported in healthy participants, which suggests that this relationship may be specific to mood disorders. Given the strong evidence on the effect of objective sleep disturbance on cognitive impairment in healthy individuals (Krause et al., 2017), this may indicate that subjective experience of sleep impairment may also increase risks for cognitive impairment in people with mood disorders. Some studies also found a curvilinear association, indicating that both extremely low (<5 h) and extremely high (>11 h) self-reported sleep durations were associated with cognitive impairment; this was observed in participants with MDD (e.g. Müller et al., 2017) and in BD (e.g. Laskemoen et al., 2019). However, there was also evidence to suggest that insomnia may have more deleterious effects on cognitive impairment than hypersomnia. For example, Laskemoen et al. (2019) found a larger effect size between insomnia and processing speed ($F = 15.43$, $p < 0.001$, $\eta^2 = 0.019$) than hypersomnia ($F = 6.87$, $p < 0.01$, $\eta^2 = 0.009$) in people with BD.

Only three studies included in this review measured sleep disturbance using objective measures: two examined sleep disturbance in participants with BD using actigraphy (Boland et al., 2015; Bradley et al., 2020) and one investigated sleep disturbance in participants with MDD using PSG (Wilckens et al., 2020). The MDD study that used PSG found that longer periods of wakefulness occurring after defined sleep onset were associated with psychomotor slowing, however these associations were not specific to MDD (Wilckens et al., 2020). One advantage of PSG is that it is more accurate than actigraphy in recognising sleep and wake times, and is therefore the ‘gold standard’ of objective sleep measurement. Another key advantage of PSG is the ability to measure sleep architecture, however, Wilckens et al. (2020) did not report sleep architecture measurements.

Kanady et al. (2017) was the only RCT included in this review. This study, in which CBTI-BD (Harvey et al., 2015) was administered to participants with BD, found that a reduction in total wake time predicted improved working memory. The study also found that a reduction in sleep time variability predicted improved verbal learning. These findings suggest that sleep disturbance may contribute to cognitive impairment in BD, and that CBTI-BD may be an effective treatment. The remaining studies included in our review used either a longitudinal or cross-sectional design, and therefore did not allow for causal inferences to be made.

The main disadvantage of using subjective measures to assess sleep disturbance in people with mood disorders is that there is a considerable risk of bias. Euthymic people with either BD or MDD tend to significantly underestimate sleep duration and quality (Harvey et al., 2005; Carney et al., 2011). Indeed, Boland et al. (2015) found that people with BD had significantly higher insomnia severity index (ISI) scores than healthy participants (indicating worse sleep quality), yet found no significant difference between BD and healthy participants in objective sleep parameters, as measured by actigraphy. This effect may be due to maladaptive sleep-related beliefs developed during mood episodes, in which sleep disturbance is particularly severe, which are then carried over into euthymia (Carney et al., 2011). Nevertheless, subjective measures provide valuable information about the perception of sleep disturbance and sleep-related cognitions, and interventions of maladaptive sleep beliefs may be a useful way of treating sleep disturbance in mood disorders (Morin et al., 2002). Although antidepressant treatment produces no

change in maladaptive sleep beliefs in MDD (Carney et al., 2011), Cognitive Behavioural Treatment for Insomnia (CBT-I) has been shown to significantly improve maladaptive sleep beliefs in people with insomnia. CBT-I has been found to significantly improve both subjective sleep measures, measured by sleep diaries, and objective sleep measures, measured by polysomnography (PSG) (Morin et al., 2002). Therefore, sleep-related cognitions may be an important target for treating sleep disturbance and potentially cognitive impairment in people with mood disorders.

Mood disorders are associated with several sleep architecture abnormalities, particularly altered distribution of rapid eye movement (REM) sleep in MDD (Hutka et al., 2021) and BD (Eidelman et al., 2010). Components of sleep architecture have been linked to aspects of cognitive impairment in healthy individuals. For example, time in slow wave sleep contributes to processing speed in healthy individuals (della Monica et al., 2018). Abnormal sleep architecture may be associated with cognitive impairment in mood disorders, so sleep architecture may be a highly relevant variable to measure. Moreover, knowledge of the specific components of sleep architecture associated with improvements in mental health or cognition could be targeted in interventions for treatment or prevention. For example, enhancing slow oscillation activity via non-invasive auditory stimulation has been shown to improve memory in healthy individuals (Ngo et al., 2013). Thus, we suggest that future studies of the role of sleep in cognition in mood disorders use PSG where possible. It is worth noting that there is a well-known ‘first night effect’ in PSG, characterised by decreased total sleep time, decreased sleep efficiency and reduction of REM sleep on the first night of measurement (Agnew et al., 1966), so future PSG studies should ideally be conducted over multiple nights to allow for a more accurate assessment. However, we accept that practical limitations may prevent this, and acknowledge that actigraphy is a viable alternative to PSG for measuring sleep-wake cycles, with the advantages of being non-invasive and relatively low cost.

Interestingly, the two BD studies which used actigraphy had opposite findings. Bradley et al. (2020) found a significant association between objective sleep disturbance and cognitive impairment in participants with BD ($p < 0.001$). Specifically, participants with BD and abnormal sleep patterns were found to experience deficits in attention and executive function but normal verbal memory. In contrast, Boland et al. (2015) found no significant association between objective sleep disturbance and cognitive impairment in participants with BD. However, this study included a relatively small sample size of participants with BD ($n = 24$) which implies low statistical power and risk of type-II error. Nevertheless, taken together, these two BD studies are inconclusive as to the association between objective sleep disturbance and cognitive impairment in people with BD and highlights the need for future research using larger sample sizes and PSG.

In studies examining sleep disturbance and cognitive impairment in mood disorders, it is normally best practice to include only euthymic participants because mood state may affect both sleep disturbance and cognitive impairment, and therefore may be a confound (Miskowiak et al., 2018). The MDD studies were particularly weak in this regard; the BD studies were stronger, but still varied. However, in comparing across studies, it is apparent that mood state did not seem to significantly affect the relationship between sleep disturbance and cognitive impairment. In BD, of the six studies that reported significant associations, five included euthymic participants and one included participants in any mood state; and of the two that reported non-significant associations, one included euthymic participants and one included participants in any mood state. In MDD, of the four studies that reported significant associations, three included participants currently experiencing an MDE and one included euthymic participants with remitted MDD; and the one study that reported non-significant associations included participants currently experiencing an MDE. Therefore, there did not seem to be a clear trend between the mood state of participants and significance of results.

With the exception of Wilckens et al. (2020), none of the included

studies adjusted for the use of psychotropic medications in the relationship between sleep disturbance and cognitive impairment. Psychotropic medication may be a confounding variable, as they can affect both sleep and cognition in people with mood disorders (Staner, 2005). Indeed, Volkert et al. (2015) reported that antipsychotic treatment and polypharmacy were related to cognitive impairment. Furthermore, many antipsychotics affect REM sleep, which has been linked to emotional memory processing (Walker and van Der Helm, 2009). Without adjusting for the use of psychotropic medications, it is unclear which medications alter the relationship between sleep disturbance and cognitive impairment in mood disorders, and to what extent.

4.1. Limitations

This review reflects the limited number of studies in the field and so the relatively small number of participants in which the associations between sleep disturbance and cognitive impairment have been investigated, particularly regarding MDD, limits our power to draw wider conclusions. The studies included in our review generally had small sample sizes of participants with mood disorders ($N = 24$ –777), which limited statistical power and increased risks of type-II error. A meta-analysis was not performed because there was significant heterogeneity between studies in the age and mood state of participants, as well as the measures of sleep and cognition used. This review did not include studies of participants with comorbid neurological disorders such as dementia or MCI.

4.2. Suggestions for future research

Theoretically, sleep disturbance may cause, predispose or exacerbate cognitive impairment in mood disorders, but this link has yet to be conclusively evaluated. It is also possible that cognitive impairment is a causal factor of sleep disturbance, or indeed that there is a single causal factor of both sleep disturbance and cognitive impairment. Further research is clearly needed in this area in participants with mood disorders. Based on the evaluation of current evidence, we would suggest that future studies follow five recommendations. First, studies should include only euthymic participants, to remove the confounding effect of mood state. Second, they should use objective measures of sleep, ideally PSG, to evaluate the role of sleep disturbance in mediating cognitive impairment, and to determine which aspects of sleep architecture are linked to cognition in these individuals. Third, all studies should use a comprehensive cognitive battery such as the BACS-A (Keefe et al., 2004) or ideally the ISBD-BANC, which is suitable for use in BD as it includes complex verbal learning measures and tests of executive function, which are among the cognitive measures that show the greatest impairment in BD (Yatham et al., 2010). Fourth, analyses should adjust for the use of psychotropic medications, as these may also have a confounding effect. Finally, we would suggest that studies use a prospective longitudinal design, and, if possible, use a randomised clinical trial design for intervention studies.

5. Conclusion

In conclusion, our systematic review provides preliminary evidence for an association between sleep disturbance and cognitive impairment in mood disorders. The studies identified by this systematic review found increased rates of both subjective sleep disturbances and cognitive impairment in people with MDD and BD, compared to healthy participants. Ten of the twelve studies that measured sleep disturbance using *subjective* measures of sleep found a significant association between sleep disturbance and cognitive impairment across both diagnoses when adjusting for demographic and clinical covariates, whereas no significant association was found in healthy participants. In contrast, the evidence was scarcer and more conflicting with regards to whether *objectively* measured sleep abnormalities are associated with cognitive

impairment in people with mood disorders: two out of three studies reported significant associations. Only one study (Kanady et al., 2017) conducted an intervention, and reported that improved sleep predicted an improvement in cognition in BD. As cognitive impairment has significant implications for psychosocial functioning, these findings highlight the need for further research of sleep disturbances and cognitive impairment in people with mood disorders.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jad.2023.01.114>.

CRedit authorship contribution statement

OP wrote the report with input from NUM, KWM, SAC, IR, AHY and PRAS. OP and NUM independently performed the literature search and quality assessment. All authors had full access to all the papers in the study and had final responsibility for the decision to submit for publication.

Conceptualisation: OP and PRAS, data curation: n/a, formal analysis: n/a, funding acquisition: n/a, investigation: OP and NUM, methodology: n/a, project administration: OP and PRAS, resources: n/a, software: n/a, supervision: PRAS, validation: OP, visualisation: OP, writing – original draft: OP, writing – review & editing: OP, NUM, KWM, SAC, IR, AHY and PRAS.

Conflict of interest

OP, NUM, SAC and IR declare no competing interests.

KWM has received consultancy fees from Lundbeck and Janssen-Cilag in the past three years.

PRAS reports non-financial support from Janssen Research and Development LLC, personal fees and non-financial support from Frontiers in Psychiatry, personal fees from Allergan, a grant from H Lundbeck, grants and non-financial support from Corcept Therapeutics, outside the submitted work.

AHY declares:

Employed by King's College London; Honorary Consultant SLaM (NHS UK).

Deputy Editor, BJPsych Open.

Paid lectures and advisory boards for the following companies with drugs used in affective and related disorders:

Astrazenaca, Eli Lilly, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, COMPASS. Consultant to Johnson & Johnson.

Consultant to Livanova.

Received honoraria for attending advisory boards and presenting talks at meetings organised by LivaNova. Principal Investigator in the Restore-Life VNS registry study funded by LivaNova.

Principal Investigator on ESKETINTRD3004: “An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression”.

Principal Investigator on “The Effects of Psilocybin on Cognitive Function in Healthy Participants”.

Principal Investigator on “The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD)”.

UK Chief Investigator for Novartis MDD study MIJ821A12201.

Grant funding (past and present): NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK). Janssen (UK).

No shareholdings in pharmaceutical companies.

Acknowledgements

None.

References

- Agnew, H.W., Webb, W.B., Williams, R.L., 1966. The first night effect, an EEG study of sleep. *Psychophysiology* 2, 263–266.
- American Psychiatric Association, 1980. *Diagnostic and Statistical Manual of Mental Disorders*, (3rd ed.).
- Aschenbrenner, S., Tucha, O., Lange, K., 2000. *Manual zum RWT (Regensburger Wortflüssigkeits-Test; Handanweisung)*.
- Ashton, J.E., Harrington, M.O., Langthorne, D., Ngo, H.-V.V., Cairney, S.A., 2020. Sleep deprivation induces fragmented memory loss. *Learn. Mem.* 27 (4), 130–135.
- Boland, E.M., Stange, J.P., Molz Adams, A., LaBelle, D.R., Ong, M.-L., Hamilton, J.L., Connolly, S.L., Black, C.L., Cedeño, A.B., Alloy, L.B., 2015. Associations between sleep disturbance, cognitive functioning and work disability in bipolar disorder. *Psychiatry Res.* 230 (2), 567–574. <https://doi.org/10.1016/j.psychres.2015.09.051>.
- Bora, E., Yucel, M., Pantelis, C., 2009. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. *J. Affect. Disord.* 113 (1–2), 1–20. <https://doi.org/10.1016/j.jad.2008.06.009>.
- Bradley, A.J., Anderson, K.N., Gallagher, P., McAllister-Williams, R.H., 2020. The association between sleep and cognitive abnormalities in bipolar disorder. *Psychol. Med.* 50 (1), 125–132. <https://doi.org/10.1017/S0033291718004038>.
- Burdick, K.E., Russo, M., Frangou, S., Mahon, K., Braga, R.J., Shanahan, M., Malhotra, A. K., 2014. Empirical evidence for discrete neurocognitive subgroups in bipolar disorder: clinical implications. *Psychol. Med.* 44 (14), 3083–3096. <https://doi.org/10.1017/S0033291714000439>.
- Buyse, D.J., Reynolds III, C.F., Monk, T.H., Berman, S.R., Kupfer, D.J., 1989. The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. *Psychiatry Res.* 28 (2), 193–213.
- Cabanel, N., Schmidt, A.-M., Fockenberg, S., Brückmann, K.F., Haag, A., Müller, M.J., Kundermann, B., 2019. Evening preference and poor sleep independently affect attentional-executive functions in patients with depression. *Psychiatry Res.* 281, 112533 <https://doi.org/10.1016/j.psychres.2019.112533>.
- Cambridge, O.R., Knight, M.J., Mills, N., Baune, B.T., 2018. The clinical relationship between cognitive impairment and psychosocial functioning in major depressive disorder: a systematic review. *Psychiatry Res.* 269, 157–171. <https://doi.org/10.1016/j.psychres.2018.08.033>.
- Carney, C.E., Segal, Z.V., Edinger, J.D., Krystal, A.D., 2007. A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. *J. Clin. Psychiatry* 68 (2), 254–60.
- Carney, C.E., Harris, A.L., Friedman, J., Segal, Z.V., 2011. Residual sleep beliefs and sleep disturbance following cognitive behavioral therapy for major depression. *Depress. Anxiety* 28 (6), 464–470.
- Cha, D.S., Carmona, N., Cha, R.H., Zhou, A.J., Subramaniapillai, M., Mansur, R.B., Lee, Y., Lee, J.H., Lee, J., Almatham, F., Alageel, A., Rosenblat, J.D., Shekothikhina, M., Rong, C., Harrison, J., McIntyre, R.S., 2019. Perceived sleep quality predicts cognitive function in adults with major depressive disorder independent of depression severity. *Ann. Clin. Psychiatry* 10.
- Delis, D.C., Kramer, J.H., Kaplan, E., Holdnack, J., 2004. Reliability and validity of the delis-Kaplan executive function system: an update. *J. Int. Neuropsychol. Soc.* 10 (2), 301.
- della Monica, C., Johnsen, S., Atzori, G., Groeger, J.A., Dijk, D.-J., 2018. Rapid eye movement sleep, sleep continuity and slow wave sleep as predictors of cognition, mood, and subjective sleep quality in healthy men and women, aged 20–84 years. *Frontiers in Psychiatry* 9, 255. <https://doi.org/10.3389/fpsy.2018.00255>.
- Depp, C.A., Mautsach, B.T., Harmell, A.L., Savla, G.N., Bowie, C.R., Harvey, P.D., Patterson, T.L., 2012. Meta-analysis of the association between cognitive abilities and everyday functioning in bipolar disorder. *Bipolar Disord.* 14 (3), 217–226.
- Depp, C.A., Dev, S., Eyster, L.T., 2016. Bipolar depression and cognitive impairment. *Psychiatr. Clin. N. Am.* 39 (1), 95–109. <https://doi.org/10.1016/j.psc.2015.09.004>.
- Diagnostic and Statistical Manual of Mental Disorders: DSM-5, (5th ed), 2013. American Psychiatric Association.
- Dinges, D.F., Powell, J.W., 1985. Microcomputer analyses of performance on a portable, simple visual RT task during sustained operations. *Behav. Res. Methods Instrum. Comput.* 17 (6), 652–655.
- Eidelman, P., Talbot, L.S., Gruber, J., Hairston, I., Harvey, A.G., 2010. Sleep architecture as correlate and predictor of symptoms and impairment in inter-episode bipolar disorder: taking on the challenge of medication effects: sleep and inter-episode bipolar disorder. *J. Sleep Res.* 19 (4), 516–524. <https://doi.org/10.1111/j.1365-2869.2010.00826.x>.
- Endicott, J., Spitzer, R., 1987. Schedule for affective disorders and schizophrenia (SADS). *Acta Psychiatr. Belg.* 87 (4), 361–516.
- Fan, J., McCandliss, B.D., Sommer, T., Raz, A., Posner, M.I., 2002. Testing the efficiency and independence of attentional networks. *J. Cogn. Neurosci.* 14 (3), 340–347.
- Fietze, I., Wiesenacker, D., Blau, A., Penzel, T., 2008. Sleep quality in a hospital and effects of noise. *Somnologie* 12 (2), 167.
- Glahn, D.C., Almas, L., Barguil, M., Hare, E., Peralta, J.M., Kent, J.W., Dassori, A., Contreras, J., Pacheco, A., Lanzagorta, N., 2010. Neurocognitive endophenotypes for bipolar disorder identified in multiplex multigenerational families. *Arch. Gen. Psychiatry* 67 (2), 168–177.
- Harrington, M.O., Cairney, S.A., 2021. Sleep loss gives rise to intrusive thoughts. *Trends Cogn. Sci.* 25 (6), 434–436.
- Harrington, M.O., Ashton, J.E., Sankarasubramanian, S., Anderson, M.C., Cairney, S.A., 2021. Losing Control: Sleep Deprivation Impairs the Suppression of Unwanted Thoughts, 17.
- Harvey, A.G., Schmidt, D.A., Scarnà, A., Semler, C.N., Goodwin, G.M., 2005. Sleep-related functioning in euthymic patients with bipolar disorder, patients with

- insomnia, and subjects without sleep problems. *Am. J. Psychiatr.* 162 (1), 50–57. <https://doi.org/10.1176/appi.ajp.162.1.50>.
- Harvey, A.G., Soehner, A.M., Kaplan, K.A., Hein, K., Lee, J., Kanady, J., Li, D., Rabe-Hesketh, S., Ketter, T.A., Neylan, T.C., Bussey, D.J., 2015. Treating insomnia improves mood state, sleep, and functioning in bipolar disorder: a pilot randomized controlled trial. *J. Consult. Clin. Psychol.* 83 (3), 564–577. <https://doi.org/10.1037/a0038655>.
- Hutka, P., Krivosova, M., Muchova, Z., Tonhajzerova, I., Hamrakova, A., Mlynckekova, Z., Mokry, J., Ondrejka, I., 2021. Association of Sleep Architecture and Physiology with depressive disorder and antidepressants treatment. *Int. J. Mol. Sci.* 22 (3), 1333. <https://doi.org/10.3390/ijms22031333>.
- Iovieno, N., van Nieuwenhuizen, A., Clain, A., Baer, L., Nierenberg, A.A., 2011. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. *Depress. Anxiety* 28 (2), 137–144.
- Jackson, A., Cavanagh, J., Scott, J., 2003. A systematic review of manic and depressive prodromes. *J. Affect. Disord.* 74 (3), 209–217.
- Jensen, J.H., Knorr, U., Vinberg, M., Kessing, L.V., Miskowiak, K.W., 2016. Discrete neurocognitive subgroups in fully or partially remitted bipolar disorder: associations with functional abilities. *J. Affect. Disord.* 205, 378–386.
- Johns, M.W., 1991. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep* 14 (6), 540–545.
- Kanady, J.C., Soehner, A.M., Klein, A.B., Harvey, A.G., 2017. The association between insomnia-related sleep disruptions and cognitive dysfunction during the inter-episode phase of bipolar disorder. *J. Psychiatr. Res.* 88, 80–88. <https://doi.org/10.1016/j.jpsychires.2017.01.001>.
- Kaufman, A.S., 1990. *Manual for the Kaufman Brief Intelligence Test*. American Guidance Service, Circle Pines, MN.
- Keefe, R.S., Goldberg, T.E., Harvey, P.D., Gold, J.M., Poe, M.P., Coughenour, L., 2004. The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. *Schizophr. Res.* 68 (2–3), 283–297.
- Krause, A.J., Simon, E.B., Mander, B.A., Greer, S.M., Saletin, J.M., Goldstein-Piekarski, A.N., Walker, M.P., 2017. The sleep-deprived human brain. *Nat. Rev. Neurosci.* 18 (7), 404–418. <https://doi.org/10.1038/nrn.2017.55>.
- Kurtz, M.M., Gerraty, R.T., 2009. A meta-analytic investigation of neurocognitive deficits in bipolar illness: profile and effects of clinical state. *Neuropsychology* 23 (5), 551–562. <https://doi.org/10.1037/a0016277>.
- Laskemoen, J.F., Büchmann, C., Barrett, E.A., Collier-Høegh, M., Haatveit, B., Vedal, T.J., Ueland, T., Melle, I., Aas, M., Simonsen, C., 2019. Do sleep disturbances contribute to cognitive impairments in schizophrenia spectrum and bipolar disorders? *Eur. Arch. Psychiatry Clin. Neurosci.* <https://doi.org/10.1007/s00406-019-01075-0>.
- Li, S.X., Lam, S.P., Chan, J.W.Y., Yu, M.W.M., Wing, Y.-K., 2012. Residual sleep disturbances in patients remitted from major depressive disorder: a 4-year naturalistic follow-up study. *Sleep* 35 (8), 1153–1161. <https://doi.org/10.5665/sleep.2008>.
- Martino, D.J., Igoa, A., Scápola, M., Marengo, E., Samamé, C., Strojilovich, S.A., 2017. Functional outcome in the middle course of bipolar disorder: a longitudinal study. *J. Nerv. Ment. Dis.* 205 (3), 203–206. <https://doi.org/10.1097/nmd.0000000000000583>.
- McIntyre, R.S., Cha, D.S., Soczynska, J.K., Woldeyohannes, H.O., Gallagher, L.A., Kudlow, P., Alsuwaidan, M., Baskaran, A., 2013. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. *Depress. Anxiety* 30 (6), 515–527. <https://doi.org/10.1002/da.22063>.
- Miskowiak, K., Burdick, K., Martínez-Aran, A., Bonnin, C., Bowie, C., Carvalho, A., Gallagher, P., Lafer, B., López-Jaramillo, C., Sumiyoshi, T., McIntyre, R., Schaffer, A., Porter, R., Purdon, S., Torres, I., Yatham, L., Young, A., Kessing, L., Vieta, E., 2018. Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians. *Bipolar Disord.* 20 (3), 184–194. <https://doi.org/10.1111/bdi.12595>.
- Montgomery, S.A., Åsberg, M., 1979. A new depression scale designed to be sensitive to change. *Br. J. Psychiatry* 134 (4), 382–389.
- Morin, C.M., 1993. *Insomnia: Psychological Assessment and Management*. Guilford press.
- Morin, C., Blais, F., Savard, J., 2002. Are changes in beliefs and attitudes about sleep related to sleep improvements in the treatment of insomnia? *Behav. Res. Ther.* 40 (7), 741–752.
- Müller, M.J., Olschinski, C., Kundermann, B., Cabanel, N., 2017. Sleep duration of inpatients with a depressive disorder: associations with age, subjective sleep quality, and cognitive complaints. *Arch. Psychiatr. Nurs.* 31 (1), 77–82. <https://doi.org/10.1016/j.apnu.2016.08.008>.
- Nelson, H.E., 1982. *National Adult Reading Test (NART): For the Assessment of Premorbid Intelligence in Patients With Dementia: Test Manual*. Nfer-Nelson.
- Ngo, H.-V.V., Martinetz, T., Born, J., Mölle, M., 2013. Auditory closed-loop stimulation of the sleep slow oscillation enhances memory. *Neuron* 78 (3), 545–553.
- Niemann, H., Sturm, W., Thöne-Otto, A., Wilmes, K., 2011. *California Verbal Learning Test, Version 21*. Schuhfried GmbH, Mödling.
- Nierenberg, A.A., Keefe, B.R., Leslie, V.C., Alpert, J.E., Pava, J.A., Worthington, J.J., Fava, M., 1999. Residual symptoms in depressed patients who respond acutely to fluoxetine. *J. Clin. Psychiatry* 60 (4), 221–225.
- O'Donnell, L.A., Deldin, P.J., Grogan-Kaylor, A., McClinnis, M.G., Weintraub, J., Ryan, K.A., Himle, J.A., 2017. Depression and executive functioning deficits predict poor occupational functioning in a large longitudinal sample with bipolar disorder. *J. Affect. Disord.* 215, 135–142. <https://doi.org/10.1016/j.jad.2017.03.015>.
- Page, M.J., McKenzie, J.E., Bossuyt, P.M., Boutron, I., Hoffmann, T.C., Mulrow, C.D., Shamseer, L., Tetzlaff, J.M., Akl, E.A., Brennan, S.E., Chou, R., Glanville, J., Grimshaw, J.M., Hróbjartsson, A., Lalu, M.M., Li, T., Loder, E.W., Mayo-Wilson, E., McDonald, S., Moher, D., 2021. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* n71. <https://doi.org/10.1136/bmj.n71>.
- Pariante, C.M., Alhaj, H.A., Arulnathan, V.E., Gallagher, P., Hanson, A., Massey, E., McAllister-Williams, R.H., 2012. Central glucocorticoid receptor-mediated effects of the antidepressant, citalopram, in humans: a study using EEG and cognitive testing. *Psychoneuroendocrinology* 37 (5), 618–628.
- Peng, S., Li, J., Wu, Z., Cao, W., Jian, Y., Lu, Y., Pei, C., 2018. Characteristics of and factors influencing cognitive impairment in adolescent patients with first-episode depression. *Vulnerable Child. Youth Stud.* 13 (4), 317–324. <https://doi.org/10.1080/17450128.2018.1515517>.
- Pu, S., Noda, T., Setoyama, S., Nakagome, K., 2018. Empirical evidence for discrete neurocognitive subgroups in patients with non-psychotic major depressive disorder: clinical implications. *Psychol. Med.* 48 (16), 2717–2729. <https://doi.org/10.1017/S00329171800034X>.
- Rock, P., Roiser, J., Riedel, W., Blackwell, A., 2014. Cognitive impairment in depression: a systematic review and meta-analysis. *Psychol. Med.* 44 (10), 2029.
- Rosa, A.R., Sánchez-Moreno, J., Martínez-Aran, A., Salamero, M., Torrent, C., Reinares, M., Comes, M., Colom, F., Van Riel, W., Ayuso-Mateos, J.L., 2007. Validity and reliability of the functioning assessment short test (FAST) in bipolar disorder. *Clin. Pract. Epidemiol. Ment. Health* 3 (1), 5.
- Rush, A.J., Gullion, C.M., Basco, M.R., Jarrett, R.B., Trivedi, M.H., 1996. The inventory of depressive symptomatology (IDS): psychometric properties. *Psychol. Med.* 26 (3), 477–486.
- Russo, M., Mahon, K., Shanahan, M., Ramjas, E., Solon, C., Purcell, S.M., Burdick, K.E., 2015. The relationship between sleep quality and neurocognition in bipolar disorder. *J. Affect. Disord.* 187, 156–162. <https://doi.org/10.1016/j.jad.2015.08.009>.
- Samalin, L., Llorca, P.M., Giordana, B., Milhiet, V., Yon, L., El-Hage, W., Courtet, P., Haques, E., Bedira, N., Filipovics, A., 2014. Residual symptoms and functional performance in a large sample of euthymic bipolar patients in France (the OPTHYUM study). *J. Affect. Disord.* 159, 94–102.
- Samalin, L., de Chazeron, I., Vieta, E., Bellivier, F., Llorca, P.-M., 2016. Residual symptoms and specific functional impairments in euthymic patients with bipolar disorder. *Bipolar Disord.* 18 (2), 164–173. <https://doi.org/10.1111/bdi.12376>.
- Samalin, L., Boyer, L., Murru, A., Pachiarotti, I., Reinares, M., Bonnin, C.M., Torrent, C., Verdolini, N., Pancheri, C., de Chazeron, I., Boucekine, M., Geoffroy, P.-A., Bellivier, F., Llorca, P.-M., Vieta, E., 2017. Residual depressive symptoms, sleep disturbance and perceived cognitive impairment as determinants of functioning in patients with bipolar disorder. *J. Affect. Disord.* 210, 280–286. <https://doi.org/10.1016/j.jad.2016.12.054>.
- Semkowska, M., Quinlivan, L., O'Grady, T., Johnson, R., Collins, A., O'Connor, J., Knittle, H., Ahern, E., Glod, T., 2019. Cognitive function following a major depressive episode: a systematic review and meta-analysis. *Lancet Psychiatry* 6 (10), 851–861. [https://doi.org/10.1016/S2215-0366\(19\)30291-3](https://doi.org/10.1016/S2215-0366(19)30291-3).
- Shallice, T., 1982. Specific impairments of planning. *Philos. Trans. R. Soc. Lond. B* 298 (1089), 199–209.
- Snyder, H.R., 2013. Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review. *Psychol. Bull.* 139 (1), 81–132. <https://doi.org/10.1037/a0028727>.
- Soehner, A.M., Harvey, A.G., 2012. Prevalence and functional consequences of severe insomnia symptoms in mood and anxiety disorders: results from a nationally representative sample. *Sleep* 35 (10), 1367–1375. <https://doi.org/10.5665/sleep.2116>.
- Staner, L., 2005. Sleep disturbances, psychiatric disorders, and psychotropic drugs. *Dialogues Clin. Neurosci.* 7 (4), 323.
- Sylvia, L.G., Dupuy, J.M., Ostacher, M.J., Cowperthwait, C.M., Hay, A.C., Sachs, G.S., Nierenberg, A.A., Perlis, R.H., 2012. Sleep disturbance in euthymic bipolar patients. *J. Psychopharmacol.* 26 (8), 1108–1112. <https://doi.org/10.1177/0269881111421973>.
- Thomas, H., Ciliska, D., Dobbins, M., 2003. *Quality Assessment Tool for Quantitative Studies*. Effective Public Health Practice Project McMaster University, Toronto.
- Ullah, M.H., 2017. *Effects of Sleep Disturbance on Cognitive Functioning in Bipolar Disorder Type 1: A Correlational Study Design*. ProQuest Dissertations Publishing.
- Volkert, J., Kopf, J., Kazmaier, J., Glaser, F., Zierhut, K.C., Schiele, M.A., Kittel-Schneider, S., Reif, A., 2015. Evidence for cognitive subgroups in bipolar disorder and the influence of subclinical depression and sleep disturbances. *Eur. Neuropsychopharmacol.* 25 (2), 192–202. <https://doi.org/10.1016/j.euroneuro.2014.07.017>.
- Walker, M.P., van Der Helm, E., 2009. Overnight therapy? The role of sleep in emotional brain processing. *Psychol. Bull.* 135 (5), 731.
- Wechsler, D., 1997. *Wechsler Memory Scale (WMS-III)*, 14. Psychological corporation San Antonio, TX.
- Wechsler, D., 2001. *Wechsler Test of Adult Reading: WTAR*. Psychological Corporation, San Antonio, TX.
- White, D.A., Myerson, J., Hale, S., 1997. How cognitive is psychomotor slowing in depression? Evidence from a meta-analysis. *Aging Neuropsychol. Cognit.* 4 (3), 166–174. <https://doi.org/10.1080/13825589708256645>.
- Wilckens, K.A., Kline, C.E., Bowman, M.A., Brindle, R.C., Cribbet, M.R., Thayer, J.F., Hall, M.H., 2020. Does objectively-assessed sleep moderate the association between history of major depressive disorder and task-switching? *J. Affect. Disord.* 265, 216–223. <https://doi.org/10.1016/j.jad.2020.01.003>.
- Woods, S.P., Delis, D.C., Scott, J.C., Kramer, J.H., Holdnack, J.A., 2006. *The California verbal learning test—second edition: test-retest reliability, practice effects, and reliable change indices for the standard and alternate forms*. *Arch. Clin. Neuropsychol.* 21 (5), 413–420.

- World Health Organization, 1988. International classification of diseases—ninth revision (ICD-9). *Wkly Epidemiol. Rec.* 63 (45), 343–344.
- Wysokinski, A., Dzienniak, M., Kloszewska, I., 2014. Assessment of cognitive performance using CNS vital signs after electroconvulsive treatment of schizophrenia. *J. ECT* 30 (1), e5–e6.
- Yatham, L.N., Torres, I.J., Malhi, G.S., Frangou, S., Glahn, D.C., Bearden, C.E., Burdick, K.E., Martínez-Arán, A., Dittmann, S., Goldberg, J.F., 2010. The international society for bipolar disorders–battery for assessment of neurocognition (ISBD-BANC). *Bipolar Disord.* 12 (4), 351–363.
- Zhang, B.-H., Feng, L., Feng, Y., Xin, L.-M., Zhu, X.-Y., Tan, Y.-L., Wang, G., 2020. The effect of cognitive impairment on the prognosis of major depressive disorder. *J. Nerv. Ment. Dis.* 208 (9). https://journals.lww.com/jonmd/Fulltext/2020/09000/The_Effect_of_Cognitive_Impairment_on_the.8.aspx.
- Zimmermann, P., Fimm, B., 2002. A test battery for attentional performance. In: *Applied Neuropsychology of Attention. Theory, Diagnosis and Rehabilitation*, 110, p. 151.